Related Experiment Video
Updated: Jun 13, 2026
13:04
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
A comprehensive hepatitis C viral kinetic model explaining cure.
E Snoeck1, P Chanu, M Lavielle
1Exprimo NV, Mechelen, Belgium.
Clinical Pharmacology and Therapeutics
|May 14, 2010
Summary
This study introduces a new hepatitis C viral kinetics model to predict treatment success. The model accurately links viral behavior to sustained virologic response (SVR) in chronic hepatitis C patients.
Area of Science:
- Virology
- Pharmacometrics
- Clinical Medicine
Background:
- Chronic hepatitis C (CHC) treatment efficacy is assessed by sustained virologic response (SVR).
- Understanding viral kinetics is crucial for predicting treatment outcomes.
- Peginterferon alpha-2a +/- ribavirin is a standard CHC treatment regimen.
Purpose of the Study:
- To develop and validate a novel hepatitis C viral kinetics model.
- To link viral complexity and diversity to SVR in CHC patients.
- To provide a framework for personalized CHC treatment strategies.
Main Methods:
- Implementation of a cure/viral eradication boundary.
- Utilization of all hepatitis C virus (HCV) RNA measurements, including those below the lower limit of quantification (LLOQ).
- Application of a population modeling approach.
Main Results:
- The model demonstrated high predictive values for SVR: positive predictive value of 99.3% and negative predictive value of 97.1%.
- The model achieved high sensitivity (96.6%) and specificity (99.4%) in predicting SVR.
- The model successfully characterized the complexity and diversity of viral kinetics.
Conclusions:
- The proposed viral kinetic model accurately predicts SVR in CHC patients.
- This model offers a framework for mechanistic exploration of treatment outcomes.
- The model facilitates the evaluation of alternative CHC treatments and personalized medicine approaches.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
A recent model describes pravastatin's hepatobiliary excretion, mediated...
01:14Pharmacokinetic–Pharmacodynamic Relationship: Model Components
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
01:20Pharmacokinetic Models: Overview
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...